Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Tumor biomarkers

Tumor biomarkers are molecules or substances found in blood, tissues, or other bodily fluids that indicate the presence or progression of cancer. They can be proteins, genes, or other indicators linked to tumor activity and help in diagnosing, predicting prognosis, and monitoring treatment responses. Biomarkers are essential for personalizing treatment plans and assessing the effectiveness of therapies. Advancements in biomarker research aim to improve early detection and precision medicine.

Tumor biomarkers

Expert PPTs

Speaker PPTs

  • Thomas Böldicke
    Intrabodies against the Polysialyltransferases ST8SiaII and ST8SiaIV inhibit Polysialylation of NCAM in rhabdomyosarcoma tumor cells
    PPT Version | PDF Version
  • Hedef Dhafir El-Yassin
    The Immune Response of Prolactin and the Induction of Tumor Necrosis Factor (TNF) in Iraqi Patients Infected with Hepatitis C Virus
    PPT Version | PDF Version
  • Moshe Giladi
    Tumor Treating Fields (TTFields) induced cancer cell death may be immunogenic resulting in enhanced antitumor efficacy when combined with immune-modulating therapy
    PPT Version | PDF Version
  • M Shahnawaz Khan
    Graphene Oxide @ Gold Nanorods Conjugate for Controlled Release of Doxorubicin in tumor
    PPT Version | PDF Version
  • Omar E Franco
    Heterogeneous Tumor Stroma and Prostate Carcinogenesis
    PPT Version | PDF Version
  • Saroj Velamakanni
    Multiparameter analysis using cell cycle biomarkers for breast cancer: Prognostic and predictive implications
    PPT Version | PDF Version
  • Yen-Chein Lai
    Molecular pathogenesis in granulosa cell tumor is not only due to somatic FOXL2 mutation
    PPT Version | PDF Version
  • Babak Behnam
    SLUG and SOX9 Cooperatively Regulate Tumor Initiating Niche Factors in Breast Cancer
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Fan-Gang Tseng
    Fan-Gang-Tseng-National-Tsing-Hua-University-Taiwan-Nano-Micro-fluidic-systems-for-circulating-Tumor-Cells-(CTCs)-rapid-detection-and-diagnosis
    PPT Version | PDF Version
  • Myron R Szewczuk
    Therapeutic targeting neuraminidase-1 in multi-stage of tumorigenesis
    PPT Version | PDF Version
  • Hawa ZE Jaafar
    Involvement of elicitated Labisia pumila Benth. biofluids in the alleviation of chemotoxicity effect and antitumor activity
    PPT Version | PDF Version
  • Huidi Liu
    Reduced Expression of SOX7 in Ovarian Cancer: a Novel Tumor Suppressor through the Wnt/β-catenin Signaling Pathway
    PPT Version | PDF Version
  • Sergey Suchkov
    Translational tools as applicable to autoimmune disorders: antibody-proteases as a generation of highly informative and unique biomarkers to monitor subclinical and clinical stages of demyelination in multiple sclerosis (MS)
    PPT Version | PDF Version
  • Alex Soltermann
    Lung neuroendocrine tumors: Correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN
    PPT Version | PDF Version
  • Mohamed Hamdy Ibrahim
    Prevalence of venous sinus stenosis in Pseudo Tumor Cerebri (PTC) using Digital Subtraction Angiography (DSA)
    PPT Version | PDF Version
  • K Ludwig
    Targeting microtentacles on circulating breast tumor cells to reduce metastasis
    PPT Version | PDF Version
  • Lei Huo
    Diagnostic biomarkers in metastatic breast cancer
    PPT Version | PDF Version
  • Amila Orucevic
    Prognostic value of ER, PR, and HER2 breast cancer biomarkers and AJCC’s TNM staging system on overall survival of Caucasian females with breast cancer: An institution’s 10 year experience
    PPT Version | PDF Version
  • Paul A Beavis
    Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced anti-tumor T cell responses
    PPT Version | PDF Version
  • Kirill Shlyapnikov
    Fibromyalgia and chronic fatigue syndrome (CFS): translational biomarkers as applicable to monitor and to predict clinical manifestations
    PPT Version | PDF Version
  • Myron R Szewczuk
    Transcriptional factor Snail and MMP-9 signaling axis controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma
    PPT Version | PDF Version
  • Ruo-Pan Huang
    Cytokine arrays reveal “Black Ops” tactics of tumor-induced immunosuppression
    PPT Version | PDF Version
  • Haya Azouz
    Gastrointestinal stromal tumor (GIST) of the adrenal gland responding markedly to imatinib: A rare case report
    PPT Version | PDF Version
  • Soo-Young Yoon
    Isocitrate dehydrogenase 1 (IDH1) mutation-specific twelve microRNA signatures as prognostic biomarkers in acute myeloid leukemia
    PPT Version | PDF Version
  • Chien-Fu Hung
    Mark cancer cells for CTL attack through coating with viral antigenic peptides CTLs kill tumor with viral peptides
    PPT Version | PDF Version
  • Catalina Lee-Chang
    A novel aging-associated B-cell subset expressing 4-1BBL controls antitumor CD8+ Tcell response
    PPT Version | PDF Version
  • Effie Liakopoulou
    Whole genome methodology for in silico quantification of intra tumor heterogeneity: Model for clinical applications in the treatment of patients with hematological malignancies
    PPT Version | PDF Version
  • Subbu Apparsundaram
    Biomarkers and pharmacogenomics in CNS disorders
    PPT Version | PDF Version
  • Igor Malyshev
    Physiological organization of immune response based on the homeostatic mechanism of matrix reprogramming: Implication in tumor and biotechnology
    PPT Version | PDF Version
  • Jim Klostergaard
    Magnetic vectoring for drug delivery to tumors: Past, present and is there a future?
    PPT Version | PDF Version
  • W Wagner
    Tumor regression by means of magnetic drug targeting
    PPT Version | PDF Version
  • Maria Celia Jamur
    The role of mast cell proteases in tumor angiogenesis
    PPT Version | PDF Version
  • K.V. Ovsyannikov
    K.V. Ovsyannikov
    PPT Version | PDF Version
  • Paul J. Davis
    Nanotetrac targets the thyroid hormone receptor on integrin αvβ3 on tumor cells to promote apoptosis, disorder cell defense pathways and block angiogenesis
    PPT Version | PDF Version
  • Wancai Yang
    Wancai Yang
    PPT Version | PDF Version
  • Youhe Gao
    Youhe Gao
    PPT Version | PDF Version
  • Jian Jun Wei
    MicroRNAs and the target genes in early tumorigenesis of fallopian/ovarian carcinoma
    PPT Version | PDF Version
  • Samuel C Dudley
    Novel biomarkers for diastolic heart failure
    | PDF Version
Conference Proceedings